Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 11,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

NCT01670279
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
70 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 30, 2026, 4:09 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ventriloscope Simulation Stethoscope Training in PT and AT Students (VENTAS)

NCT07559422
View directory record Official record
Conditions
Auscultation Training, Health Professions Education
Interventions
Traditional Auscultation Training, Ventriloscope Simulation Training
Behavioral
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
30
States / cities
Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

NCT00055237
View directory record Official record
Conditions
Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 30, 2026, 4:09 PM EDT
Not listed Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

NCT04688853
View directory record Official record
Conditions
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
TEG002
Biological
Lead sponsor
Gadeta B.V.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 30, 2026, 4:09 PM EDT
Not listed No phase listed Observational

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

NCT06025877
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Interventions
PrecivityAD2(TM) blood test
Other
Lead sponsor
C2N Diagnostics
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Timeline
2023 – 2025
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Recruiting No phase listed Observational

De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You

NCT05134779
View directory record Official record
Conditions
Breast Cancer
Interventions
Live Biobank
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

NCT05693142
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
RGX-202
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
1 Year and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

NCT04167553
View directory record Official record
Conditions
Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions
HM15136, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 30, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Results available

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

NCT03239470
View directory record Official record
Conditions
Pemphigus Foliaceus, Pemphigus Vulgaris
Interventions
Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Francisco, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 30, 2026, 4:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Health and Energy Through Active Living Every Day (HEALED) After Cancer Pilot Intervention for Cancer Survivors

NCT03983083
View directory record Official record
Conditions
Cancer, Quality of Life, Fatigue
Interventions
Physical activity
Behavioral
Lead sponsor
American Cancer Society, Inc.
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 30, 2026, 4:09 PM EDT
Completed No phase listed Observational

Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

NCT07224802
View directory record Official record
Conditions
PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
EXELiM assay (qRT-PCR validation), EXELiM small RNA sequencing
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 30, 2026, 4:09 PM EDT
Suspended Phase 1Phase 2 Interventional

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

NCT05200442
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions
VS-6766/avutometinib, Cetuximab, Pill Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Withdrawn No phase listed Observational

Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury

NCT01852773
View directory record Official record
Conditions
Blunt Injury
Interventions
Open repair of thoracic aorta injury, TEVAR
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 30, 2026, 4:09 PM EDT
Not listed No phase listed Observational

The Use of FlowMet-R Technology to Predict Wound Healing in CLI Patients in a Wound Care Center Setting

NCT05455554
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Flowmet-D, ABI
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
30 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 30, 2026, 4:09 PM EDT
Completed No phase listed Observational

Farber Disease Natural History Study

NCT03233841
View directory record Official record
Conditions
Farber Disease, Farber's Disease, Farber Lipogranulomatosis, Acid Ceramidase Deficiency, Ceramidase Deficiency, N-Laurylsphingosine Deacylase Deficiency, ASAH1 Mutation
Interventions
Not listed
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Oakland, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

NCT02445794
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Low dose cohort, High dose cohort
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Long Beach, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 30, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Drug · Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

NCT05932862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
XL309, Olaparib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
16
States / cities
Fountain Valley, California • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01375842
View directory record Official record
Conditions
Tumors, Hematologic Malignancies
Interventions
Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 30, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 30, 2026, 4:09 PM EDT